Contact Us
Drug Search Results
More Filters [+]

Sapanisertib

Alternative Names: sapanisertib, mln0128, tak-228, tak 228, tak228, cb-228, cb228, cb 228
Latest Update: 2024-12-18
Latest Update Note: Clinical Trial Update

Product Description

Sapanisertib is a dual TORC 1/2 inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells. These mutations are found in a considerable sub-population of patients across multiple solid tumor types. (Sourced from: https://www.calithera.com/mtorc1-2-inhibitor-sapanisertib-cb-228/)

Mechanisms of Action: mTOR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Fast Track - Lung Cancer *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sapanisertib

Countries in Clinic: Germany, United Kingdom, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Anaplastic Thyroid Carcinoma|Carcinosarcoma|Clear Cell Adenocarcinoma|Clear Cell Sarcoma|Endometrial Cancer|Endometrioid Carcinoma|Fallopian Tube Cancer|Mixed Tumor, Mullerian|Ovarian Cancer|Peritoneal Cancer|Serous Cystadenocarcinoma|Thyroid Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
FTH-PIK-201

P2

Recruiting

Endometrial Cancer

2028-09-01

DICE

P2

Completed

Clear Cell Adenocarcinoma|Ovarian Cancer|Serous Cystadenocarcinoma|Mixed Tumor, Mullerian|Fallopian Tube Cancer|Endometrioid Carcinoma|Carcinosarcoma|Clear Cell Sarcoma|Peritoneal Cancer

2023-11-30

NCT02244463

P2

Completed

Thyroid Cancer|Anaplastic Thyroid Carcinoma

2022-04-28

Recent News Events

Date

Type

Title

10/16/2024

News Article

 American Lung Association Invests $22 Million in Lung Health Research

07/17/2024

News Article

 Faeth Therapeutics to Present at Raymond James Biotech Private Company Showcase

05/30/2024

News Article

 Faeth Therapeutics to Participate in Upcoming Jefferies Investor Conference

04/16/2024

PubMed

 Differential susceptibility of cells infected with defective and intact HIV proviruses to killing by obatoclax and other small molecules.

04/10/2024

PubMed

 A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid Tumors.

03/01/2024

PubMed

 Designing patient-oriented combination therapies for acute myeloid leukemia based on efficacy/toxicity integration and bipartite network modeling.

11/08/2023

News Article

 Faeth Therapeutics to Participate in the Stifel 2023 Healthcare Conference

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions